Yabao Pharmaceutical Co., Ltd.
Form 483 issued April 20, 2022 · Beijing, China
- Observations
- 2
- Pages
- 3
- FEI number
- 3009071264
In short: On April 20, 2022, FDA issued a Form 483 with 2 observations to Yabao Pharmaceutical Co., Ltd. in Beijing, China (FEI 3009071264). Most observations concern laboratory controls; the most-cited regulation is 21 CFR 211.160 (general requirements).
At a glance
2 of 2 observations on this 483 concern laboratory controls.
Most cited: 21 CFR 211.160 (2×)
What FDA observed
Preview: the opening words of each observationDashed: section inferred by FDA Intel and checked against the regulation text
- 01
Written procedures applicable to equipment qualification…
- 02
Observation 2: scanned text, readable in the full document.
This inspection in context
Questions about this 483
What did FDA find at Yabao Pharmaceutical Co., Ltd.?
FDA listed 2 observations on this Form 483, mostly about laboratory controls. The most-cited regulation is 21 CFR 211.160 (general requirements). The opening words of each observation are shown on this page.
When was Yabao Pharmaceutical Co., Ltd. inspected by FDA?
This Form 483 is dated April 20, 2022.
How do I get the full Form 483 for Yabao Pharmaceutical Co., Ltd.?
Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.